glp 1 and liver cirrhosis Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty disease (NAFLD) non-alcoholic steatohepatitis (NASH) The weight-loss-independent hepatoprotective benefits of

AK: Writing review & editing

doi: 10.1038/s41419-020-03332-w

doi:10.1016/j.chemosphere.2012.10.039 Ryu J, Yoon Y, Oh J (2010) Occurrence of endocrine disrupting compounds and pharmaceuticals in 11 WWTPs in Seoul, Korea

many athletes use 1 to 2 grams of L-carnitine L-tartrate

13 In addition to being recommended in patients with ASCVD, GLP-1 receptor agonists are recommended for consideration as an add-on to metformin in patients without established ASCVD in whom there is a compelling need to minimize hypoglycemia, minimize weight gain, or promote weight loss

[DOI] [PubMed] [Google Scholar] Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P